VISUS LAB has successfully completed the development and registration of an innovative eyelid hygiene gel, "Blepharosept," as a cosmetic product. The product contains an innovative form of betulin — "Betusphere" — developed by Biotechnology Development (RBT). "Blepharosept" is currently being prepared for launch into retail chains.
"Betusphere" is a suspension containing amorphous particles obtained from natural betulin using a patented technology. RBT uses this formulation as an adjuvant for the development of antiviral vaccines based on surface recombinant proteins.
The integration of amorphous betulin particles into the gel formula provides prolonged anti-inflammatory and wound-healing effects aimed at relieving the symptoms of blepharitis and reducing the risk of eyelid infection. The combined action of betulin, zinc, and silver nanoparticles in "Blepharosept" creates a synergistic antimicrobial and anti-inflammatory barrier. The use of amorphous betulin particles has also improved the stability of the final product and ensured controlled release of the active substance.
According to Igor Viktorovich Krasilnikov, Director of RBT: "Collaborative developments in the fields of biotechnology and ophthalmology will yield more effective and safer broad-spectrum drugs, which is an important task for domestic healthcare."
RBT is a resident of Skolkovo and MedTech Technopark and is part of Artgen PJSC. RBT shares are available for trading on the Over-The-Counter (OTC) market of the Moscow Exchange.
VISUS LAB is a Skolkovo resident, a participant in the SibBioNOC Educational and Research Center, and a member of the BIOFARM Pharmcluster. The company specializes in the development and commercialization of innovative ophthalmic solutions and pharmaceutical products.